Vorasidenib | Search results | NICE

Showing 1 result for vorasidenib

Sort by

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)
Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.
Result type
Technology appraisal guidance
Published
29 April 2026
View recommendations for TA1147
Show all sections
Sections for TA1147